Romiplostim vs rhTPO for platelet recovery after transplant
Treatments studied
Part of Blood & lymphatic clinical trials.
This trial compares two drugs, romiplostim and rhTPO, to help increase platelet counts after a stem cell transplant in people with MDS or aplastic anemia. The goal is to see which drug works better at reducing the need for platelet transfusions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have been diagnosed with MDS or severe aplastic anemia and are scheduled for a stem cell transplant.
- Your transplant will come from a matched sibling, a half-matched family donor, an unrelated donor, or cord blood.
- You are generally well enough to undergo transplant (ECOG score 0-2).
- Between day 4 and day 10 after transplant, your platelet count stays below 20,000 and you need platelet transfusions.
- You do not have an active serious infection, recent blood clots, or certain other health issues that would make the study unsafe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if romiplostim, a drug that helps the body make platelets, can speed up platelet recovery after a special type of stem cell transplant from a half-matched donor. It may help reduce bleeding risk during the recovery period.
This trial tests romiplostim, a weekly injection, for patients with ITP (a blood disorder where the body destroys its own platelets) who did not respond to or could not tolerate oral medications. It aims to help raise platelet counts and reduce bleeding risk.
This trial tests a new combination of two medicines—romiplostim N01 (a shot to raise platelets) and rituximab (an infusion that calms the immune system)—for people with primary immune thrombocytopenia (ITP) who have not had enough improvement from oral TPO-RA pills like hetrombopag or eltrombopag. It aims to see if this combination works better and is safe.
This study tests a drug called romiplostim to help your body make platelets faster after a stem cell transplant. Platelets help your blood clot, and getting them back sooner can reduce bleeding risks and speed recovery.
This trial tests a drug called Romiplostim N01 to help platelet levels recover faster in people with blood cancers who have had a cord blood transplant. It may reduce the need for platelet transfusions and lower bleeding risk.
This trial tests whether giving a medicine called rhTPO early can help prevent low blood platelets, a common side effect of the chemotherapy used to prepare your body for a stem cell transplant. The goal is to help you recover faster and reduce the need for platelet transfusions.
Hear when a new MDS (Myelodysplastic Syndrome) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.